Blog Archive
-
▼
2007
(90)
-
▼
November
(14)
- Vectura and Sosei, Phase II Studies of QVA149 for ...
- Aeolus Pharmaceuticals, Pipeline, COPD
- Amira Pharmaceuticals, Initiates Clinical Studies ...
- NicOx, TOPIGEN initiates phase 2 proof of concept ...
- SPO Medical, New Oximetry Devices for European Mar...
- Advanced Life Sciences, Cethromycin, Second Pivota...
- Pharmion's Amrubicin, Results Compared to Standard...
- MAP Pharmaceuticals, Phase 2a Clinical Trial of Co...
- Gilead and LG Life Sciences, Global License Agreem...
- Æterna Zentaris, Multi-Center Phase 2 Trial with P...
- Alfacell's ONCONASE, Radiation Sensitizer for Lung...
- Nabi Biopharmaceuticals, NicVAX(R) , Significant R...
- Forbes Medi-Tech, Final Steps in Compound Selecti...
- Theravance, Initiation of Phase 2 Clinical Program...
-
▼
November
(14)
Nov 19, 2007
Gilead and LG Life Sciences, Global License Agreement to Advance Novel Drug Candidates for Treatment of Fibrotic Diseases
Nov. 6, 2007- ...Caspases are cellular proteases involved in processes such as apoptosis (cell death) and inflammation. By inhibiting various caspases, it may be possible to slow or stop the progression of fibrosis in the liver for patients with chronic viral hepatitis and non-alcoholic steatohepatitis (NASH), as well as potentially in other fibrotic diseases such as idiopathic pulmonary fibrosis (IPF)... Gilead's Press Release - LG Life Sciences' Press Release -